We are live on
!
Find out more
HCM
Hillman Capital Management Portfolio holdings
AUM
$144M
1-Year Est. Return
7.02%
This Fund
S&P 500
This Quarter
Est. Return
-13.18%
1 Year Est. Return
+7.02%
3 Year Est. Return
+20.27%
5 Year Est. Return
+21.27%
10 Year Est. Return
–
AUM
$275M
AUM Growth
-$39.7M
(-13%)
Cap. Flow
+$7.45M
Cap. Flow
% of AUM
2.71%
Top 10 Holdings %
Top 10 Hldgs %
35%
Holding
50
New
2
Increased
43
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$7.47M |
| 2 |
Warner Bros
WBD
|
+$4.68M |
| 3 |
Salesforce
CRM
|
+$1.49M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$1.41M |
| 5 |
Microsoft
MSFT
|
+$1.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$9.91M |
| 2 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$7.38M |
| 3 |
Becton Dickinson
BDX
|
+$129K |
| 4 |
Merck
MRK
|
+$123K |
| 5 |
CVS Health
CVS
|
+$16.9K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.33% |
| 2 | Technology | 16.2% |
| 3 | Consumer Staples | 13.92% |
| 4 | Communication Services | 13.79% |
| 5 | Financials | 10.17% |
Similar funds
AL
KK
GGI
I
AGM
PU
TP
12CM
Hillman Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Hillman Capital Management held 50 positions worth $275M, down 13% from $315M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Hillman Capital Management's Q2 2022 filing shows 2 new, 43 increased, 3 reduced and 2 closed positions. Its largest new stake was Lam Research: 156,880 shares worth $6.69M. The largest sale was Bristol-Myers Squibb, an estimated $9.91M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, down from 20% a quarter earlier, followed by Technology and Consumer Staples.
- Hillman Capital Management's largest Q2 2022 buy was Lam Research: 156,880 shares worth $6.69M.
- Hillman Capital Management added most to Warner Bros in Q2 2022, an estimated $4.68M increase.
- Hillman Capital Management's biggest Q2 2022 reduction was Becton Dickinson, cutting an estimated $129K.
- Hillman Capital Management fully exited Bristol-Myers Squibb in Q2 2022, selling an estimated $9.91M.
- Hillman Capital Management's ten largest holdings make up 35% of its $275M portfolio in Q2 2022.
- Hillman Capital Management opened 2 new positions and closed 2 in Q2 2022.
- Hillman Capital Management's portfolio value fell 13% quarter-over-quarter to $275M.
Based on Hillman Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.